Introduction
We employed extensive clinical phenotyping, exome sequencing, and expression studies to determine the genetic basis for AMS and BSS. We show that both AMS and BSS are due to dominant mutations in TWIST2 (MIM: 607556), affecting a highly conserved residue. TWIST2 (also called Dermo-1), which binds to E-box DNA motifs
) as a heterodimer with other bHLH proteins such as the ubiquitously expressed protein E12, is thought to act as a negative regulator of transcription. [35] [36] [37] [38] [39] [40] TWIST2 expression is temporally restricted and tissue specific. Dur-ing embryonic development, TWIST2 is highly expressed in the craniofacial mesenchyme and in chondrogenic precursors. Previous studies suggest that TWIST2 regulates mesenchymal stem cell differentiation and directs the development of dermal and chondrogenic tissues. 35, 38, 40, 41 Disturbance of these processes due to dominant mutations in TWIST2 could, therefore, cause the distinctive clinical features and facial patterning defects observed in AMS and BSS. Molecular analyses suggest that these mutations alter the DNA-binding activity of TWIST2, leading to both dominant-negative and gain-of-function effects.
Methods

Individuals Included in the Study
The original six family members of a pedigree including AMS- Shown are the clinical features of individuals with ablepharon macrostomia syndrome (AMS) and Barber Say syndrome (BSS) and mutation included in this study. Description of signs and symptoms adhere to the published guidelines according to the Elements for Morphology recommendations. [27] [28] [29] [30] [31] [32] [33] [34] Mutations in TWIST2 (GenBank: NM_057179.2) account for all cases in the study.
buffer three times. The tissues were fixed with 2% OsO 4 for 2 hr, washed again with 0.1 M cacodylate buffer three times, washed with water, and placed in 1% uranyl acetate for 1 hr. The tissues were subsequently serially dehydrated in ethanol and embedded in Spurr's (Electron Microscopy Sciences). Semi-thick (~1,000 nm) and thin (~80 nm) sections were obtained by utilizing the Leica ultracut-UCT ultramicrotome (Leica) and placed either on glass slides for toluidine blue staining or onto 300 mesh copper grids and stained with saturated uranyl acetate in 50% methanol and then with lead citrate. The grids were viewed in the JEM-1200EXII electron microscope (JEOL Ltd) at 80 kV and images were recorded on the XR611M, mid mounted, 10.5 Mpixel, CCD camera (Advanced Microscopy Techniques).
Fibroblast Culture
Primary dermal fibroblasts were cultured from forearm skin-punch biopsies as described. 42 Genomic DNA was extracted from AMS-3.1, -6.1, -7.1 (hyperpigmented, affected), and -7.2 and from BSS-4.2 and -6.1 dermal fibroblasts as well as ATCC adult control, AMS-7.1 (hypopigmented, unaffected), and the mother of AMS-7.2 dermal fibroblasts as unaffected control.
Genetic Analysis
Genomic DNA was extracted from whole blood of AMS- 
ChIP-Seq
Stably transfected T-REx-HeLa cells, treated for 24 hr with 1 mg/ml tetracycline to induce recombinant WT, p.Glu75Lys, p.Glu75Gln, p.Glu75Ala, and p.Gln77_Arg78dup TWIST2 overexpression, were fixed, pelleted, and frozen according to a cell fixation protocol provided by Active Motif. Sheared chromatin from T-REx HeLa cells without recombinant TWIST2 served as a negative control and was similarly fixed, pelleted, and frozen as a negative control. Chromatin shearing, ChIP, and DNA sequencing were performed by Active Motif. ChIP was performed with a monoclonal anti-FLAG M2 antibody (Sigma Aldrich). ChIPed DNA was sequenced on the Illumina NextSeq 500 platform. Short reads were aligned to human reference genome (hg19) with BWA. 46 Binding peaks were identified with MACS using standard parameters. 47 Peaks shared between different samples as well as the Jaccard coefficients representing the correlations between samples were calculated with BedTools. 48 Peaks were annotated and summarized with CEAS. 49 The consensus-binding motif for the WT TWIST2 sample peaks was determined with GEM2.5 with a minimum k-mer length of 6 and a maximum k-mer length of 20. Table S1 . TWIST2 inserts were then recombined into the Gateway mammalian expression plasmid pT-REx-DEST30 (Life Technologies) according to the manufacturer's protocol. T-REx-HeLa cells (Life Technologies) were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% (v/v) heatinactivated fetal bovine serum, 1% (v/v) penicillin-streptomycin, and 5 mg/ml blasticidin. T-REx-HeLa cells were transfected with 2.5 mg pT-REx-DEST30 vector with Lipofectamine 2000 reagent (Life Technologies) and selected with 400 mg/ml Geneticin. Individual clones were screened for TWIST2 expression before and after 24 hr treatment with 1 mg/ml tetracycline. Clones with the highest expression after 24 hr and with minimal leaky expression were chosen for use in further assays.
Zebrafish Experiments
Zebrafish (Danio rerio) were maintained under an approved animal study protocol, in accordance with the Zebrafish Book. 51 The human wild-type and mutant TWIST2 (p.Glu75Lys and p.Glu75Gln) were cloned into pCS2GW by Gateway (Life Technologies). Subcloned cDNAs were linearized and used for in vitro synthesis of capped mRNA via mMESSAGE mMACHINE SP6 Ultra Kit (Life Technologies). Wild-type embryos of Tupfel long fin (TL) strain embryos were injected at the one-cell stage with 10 pg (phenotypical analysis) or 2 pg (RNA sequencing) mRNA. Embryos were raised at 28 C in Embryo Medium (E3).
For RNA sequencing, total RNA was extracted from approximately 70 non-injected, wild-type hTWIST2 mRNA-injected, p.Glu75Lys mRNA-injected, and p.Glu75Gln mRNA-injected zebrafish embryos at shield stage in triplicate. Each embryo was microinjected with approximately 10 pg mRNA. RNA extraction was carried out with TRizol (Life Technologies BV) according to the manufacturer's recommendations. For all samples, total RNA was re-suspended in MQ water prior to sequencing. RNA-seq libraries were prepared according the TruSeq Stranded Total RNA Sample Preparation, Low Sample (LS) protocol. The 12 RNA-seq samples were run on a single HiSeq2500 flow cell. Quality control in FastQ files was performed with FastQC, followed by alignment to the zebrafish genome via STAR. 52 A second-quality control step was performed on the generated BAM files via Picards collectRNAMetrics. The read count per gene was determined by HTSeq-count and normalized with DESeq. 53 Differential expression analysis was done on the normalized read count tables. GO term analysis was carried out with Gorilla in fast mode 54, 55 on the expression profiles of the top 10,000 protein-coding genes ranked on adjusted p value from zebrafish embryos overexpressing hTWIST2 variants. The analysis was carried out on datasets of 26,457 protein-coding genes for p.Glu75Lys and p.Glu75Gln after comparison with wild-type hTWIST2-overexpressing samples.
Results
Clinical Characteristics
The clinical features of the AMS-affected cohort were previously described in the literature, and their findings and the original citations are listed in Table 1 . Overall, the persons with AMS exhibited ablepharon or microblepharon, macrostomia, varying anomalies of the nose and ears, lax redundant skin, sparse hair, variable abnormalities of the nipples, genitalia, fingers, and hands, and largely normal intellectual and motor development. AMS-6.1, AMS-7.1, and AMS-7.2 have typical facial, extremity, and adipose features typical of AMS ( Figure 1A ). Extensive craniofacial phenotyping of AMS-7.2 also identified undescribed features of harlequin-shaped eyebrows with absence of the distal third, a hypoplastic nasal dorsum with no projection of the nasal tip, absent columella, hypoplastic ala nasi, macrostomia, CL II malocclusion with 50% overbite, a Brody bite, conical shaped teeth, and a long uvula. The macrostomia was characterized by deficient lateral development of the vermillion border and an inability to raise the oral commissures upon smiling, suggesting a discontinuity of the orbicularis oris muscle. Electron microscopy of skin biopsies of AMS-7.1 and AMS-7.2 showed thin, disrupted elastic fibers with areas of amorphous deposits along abnormally oriented collagen fibers and adjacent areas of microfibrillar proliferation ( Figure 1B ). Masson-Trichrome staining showed abnormal reticulodermal collagen patterns in AMS-7.1 and AMS-7.2 ( Figure S1A ), whereas elastic fiber (Elastic Van Geison) staining appeared within normal limits ( Figure S1B ). The BSS-affected individuals exhibited ectropion, macrostomia, bulbous noses, malformed ears in the spectrum of microtia first degree, thin, redundant skin, hypertrichosis, hypoplastic nipples, and normal hands and development, together with other variable features (Table 1; Figure 1C ). Electron microscopy of the skin biopsy of BSS-3.1 showed findings similar to those of AMS, i.e., thin and long elastic fibers, abnormally oriented collagen fibers, and areas of microfibrillar proliferation and amorphous deposits ( Figure  1D ). BSS-3.1 and BSS-9.1 have not been previously reported; their clinical features are detailed in Table 1 .
DNA Studies
Initial studies were performed on two individuals with AMS (7.1 and 7.2), members of a three-generation Figure 1 . Clinical, Histological, and Molecular Defects in Ablepharon-Macrostomia Syndrome and Barber-Say Syndrome (A) Face, shoulders, and hands of AMS-6.1, AMS-7.1, and AMS-7.2, demonstrating dysmorphic features detailed in Table 1 . Shoulder photographs of AMS-6.1 and AMS-7.1 highlight Blaschko-like hyperpigmented banding indicative of mosaicism. Hands show mild cutaneous syndactyly and clinodactyly. (B) Electron microscopy of skin of unaffected control (1), AMS-6.1 (2), AMS-7.1 (3), and AMS-7.2. In (1), the elastin (asterisk) is ovoid in shape, whereas in (2), (3), and (4), the elastin appears elongated and, in some areas, fractured. Collagen fibers in (1) appear organized and are oriented in bundles. In (3) and (4), some collagen fibers appear in disarray (arrows) and show curved edges. In addition, some collagen fibers show variable diameters (6) . Surrounding the elastin in (5) (AMS-7.1) and (6) (AMS-7.2) are flocculent and amorphous deposits that disrupt organization of collagen bundles. Scale bars represent 1,000 nm (1-4) and 500 nm (5 and 6). (C) Face, back, and hands of BSS-3.1 and BSS-4.2 showing dysmorphic features detailed in Table 1 . Note hypertrichosis. (D) Electron microscopy of skin of BSS-3.1. Note the long and thin elastin fibers (asterisk) and collagen fibers in disarray (arrow) in (1). Similar to AMS, some collagen fibers show variable diameters (2) . Surrounding the elastin in (3) are flocculent and amorphous deposits that disrupt organization of elastin and collagen bundles. Scale bars represent 1,000 nm (1) and 500 nm (2 and 3).
pedigree. Targeted genetic testing, karyotype analysis, and chromosomal microarray analysis revealed no significant findings. SNP array analysis showed no anomalous regions of homozygosity or significant copy-number variants. Exome sequencing on all family members revealed a single nonsynonymous heterozygous mutation in TWIST2, c.223G>A (GenBank: NM_057179.2), encoding the predicted deleterious protein alteration p.Glu75Lys. Targeted sequencing revealed the same TWIST2 mutation in ten AMS-affected individuals from seven independent families (Table 1) (Table 1) .
In all instances in which DNA was available from both unaffected parents, the TWIST2 mutation occurred de novo in the first generation of individuals affected with AMS or BSS and was heritable in the third generation. Three disease-transmitting fathers with mild AMS or BSS and variable skin pigmentation were mosaic for a TWIST2 mutation, based upon next-generation sequencing of peripheral blood DNA (AMS-6.1) and Sanger sequencing of DNA from affected and unaffected skin (AMS-7.1)( Figure  S2) . None of the disease-causing TWIST2 mutations were present in the NIH Undiagnosed Diseases Program's exome cohort, and none were reported in public variant Protein Modeling TWIST2 contains three functional domains: basic, helix-loop-helix, and twist box (Figure 2A ). The TWIST2 alterations associated with AMS and BSS (p.Glu75Lys, p.Glu75Gln, p.Glu75Ala, and p.Gln77_Arg78dup) all fall within the basic domain of the protein, which mediates DNA binding. The residues affected in AMS and BSS are conserved from zebrafish to human (Fig-ure 2B) . In silico TWIST2 modeling suggests that muta-tions affecting the p.Glu75 residue do not alter global protein structure but could alter DNA binding ( Figure 2C ). The p.Glu75 residue is putatively oriented toward the major groove of bound DNA and in close proximity to the first two nucleotides of the E-box motif. Therefore, the mutations associated with AMS and BSS (as well as p.Gln77_Arg78dup) could alter the DNA-binding activity of TWIST2.
Wild-Type and Mutant TWIST2 Binding Sites
We characterized the binding pattern of both wild-type and mutant TWIST2 in an agnostic and genome-wide fashion. Specifically, we performed ChIP-seq on sheared cross-linked chromatin from T-REx HeLa cells overexpressing recombinant FLAG-HA-tagged TWIST2 proteins; sheared chromatin from T-REx HeLa cells without recombinant TWIST2 served as a negative control. We identified 630 binding peaks associated with wild-type TWIST2. Events associated with wild-type TWIST2 binding were significantly enriched (p < 0.05) near promoters (<1,000 bp, <2,000 bp, and <3,000 bp) as well as in 5 0 UTRs (data not shown). The consensus binding motif determined for wild-type TWIST2 was 5 0 -CATCTGG-3 0 (Figure 3A ), which represents a canonical E-box. The TWIST2 alterations (p.Glu75Lys, p.Glu75Gln, p.Glu75Ala, and p.Gln77_Arg78dup) shared only a fraction of their binding peaks with WT TWIST2 ( Figure 3B ); p.Glu75Ala and p.Gln77_Arg78dup TWIST2, both associated with BSS, shared only 25 binding peaks in common with the wild-type. A significant number of binding peaks detected for the mutant TWIST2 proteins were not detected for the wild-type protein ( Figure 3B ). (D) Appearance of mild, moderate, and severely affected embryos, and quantification of the phenotypes induced at 30 hpf by overexpression of WT, p.Glu75Lys, and p.Glu75Gln hTWIST2. Embryos were injected at the 1-cell stage with 10 pg mRNA. hTWIST2 variants induced defects in head structures and failure of the posterior end of the embryo to extend properly. The p.Glu75Lys and p.Glu75Gln mutants induced stronger developmental defects than wild-type hTWIST2 mRNA.
(E) GO term analysis on ranked gene lists from RNA-seq for p.Glu75Lys and p.Glu75Gln mRNA. Extracellular matrix, membrane, and cytoskeleton proteins are downregulated.
TWIST2 and Zebrafish Development
To elucidate the effect of TWIST2 mutations in vivo, we assessed the functional consequences of injecting wildtype and mutant (p.Glu75Lys and p.Glu75Gln) human TWIST2 (hTWIST2) mRNA into zebrafish at the 1-cell stage ( Figure 3C ). The introduction of wild-type hTWIST2 led to mild developmental defects (mainly mild brain hypoplasia) in approximately 65%of injected zebrafish ( Figure 3D ). The injection of p.Glu75Lys and p.Glu75Gln hTWIST2 RNA, however, led to predominantly intermediate and severe developmental defects, including severe head hypoplasia, unclear midbrain-hindbrain boundary, dysmorphic body trunk, and pericardial edema. These results were con-firmed in stable transgenic zebrafish lines that express human wildtype and mutant TWIST2 (p.Glu75Lys and p.Glu75Gln) under the control of a Cre-loxP inducible system ( Figure S3A ). To gain insight into the genetic processes underlying the developmental phenotypes, we performed RNA sequencing on injected embryos at shield stage. Compared to injection of wild-type hTWIST2, injection of p.Glu75Lys or p.Glu75Gln hTWIST2 caused differential expression of 162 genes from a total of 26,457 datasets (adjusted p value < 0.05); of these, 28 were common to both p.Glu75Lys and p.Glu75Gln hTWIST2 injection ( Figure S3B ) and all but one were up-or downregulated in the same fashion in both mutants ( Figure S3C ). The majority of expression changes of these target genes induced by overexpression of p.Glu75Lys and p.Glu75Gln were confirmed by analyzing the stable transgenic zebrafish embryos (Fig-ure S3D) . Gene ontology (GO) analyses revealed the greatest reduction in the expression of genes related to extracellular matrix (ECM), membrane components, and cytoskeleton (fibrils) ( Figure 3E ).
Discussion
We have shown that recurrent dominant mutations in the DNA binding domain of TWIST2 are responsible for two ectodermal dysplasias associated with congenital malformations and dysmorphic facial features, i.e., AMS and BSS. All 10 AMS-affected and 11 of 12 BSS-affected individuals carried a mutation in the highly conserved p.Glu75 amino acid (either p.Glu75Lys, p.Glu75Gln, or p.Glu75Ala). Mutations in the basic domain of TWIST2 drastically altered the spectrum of DNA binding, reducing normal binding and increasing binding to off-target sites. The dominant nature of the mutations, then, could be explained by the abnormal 50% of TWIST2 homodimers and bHLH heterodimers that either reduced binding to the normal contingent of DNA binding sites or conferred a neomorphic function by binding to other sites. Based upon the multitude of DNA binding sites affected by AMS and BSS mutations, the phenotypic manifestations of both AMS and BSS probably result from transcriptional effects on more than a single gene. Our findings support the importance of the DNA bind-ing domain of bHLH transcription factors: autosomaldominant mutations in the DNA binding domain of TWIST1 (GenBank: NM_000474.3; MIM: 601622), another member of the bHLH transcriptional regulators, have been associated with Saethre-Chotzen syndrome (MIM: 101400), which is characterized with craniosynostosis and limb abnormalities. 56, 57 Development appears to be exquisitely sensitive to the influence of TWIST2. Simple overexpression of the wildtype protein in zebrafish caused a mild developmental phenotype. In addition, although AMS and BSS result from missense mutations of the same amino acid, p.Glu75, the phenotypes depend on the substituting amino acid. A lysine at TWIST2 residue 75 results in AMS, whereas a glutamine or alanine yields BSS. This suggests that a single amino acid alteration, yielding two phenotypically distinct disorders, dictates specific groups of targeted developmental genes, some shared and some not shared between AMS and BSS ( Figure S4B ). Those genes might well encode proteins of the extracel-lular matrix, whose expression in zebrafish was downre-gulated by the mutations that cause AMS and BSS ( Figure S3 ). In fact, the phenotypes of those zebrafish are reminiscent of sly and bal mutants, 58 which are loss-of-function alleles of gamma-1-and alpha-1-laminins, key components of the extracellular matrix. TWIST2 is recognized as a key regulator of mesenchymal cell fate during embryonic development and of epithelial-mesen-chymal transition in human cancers; [59] [60] [61] [62] [63] therefore, TWIST2 mutations might alter the ECM by causing aber-rant gene expression.
We conclude that recurrent dominant mutations in the DNA binding domain of TWIST2 are responsible for AMS and BSS, ectodermal dysplasias with congenital malformations and dysmorphic facial features. All 10 AMS-affected and 11 of 12 BSS-affected individuals had an alteration in p.Glu75 of TWIST2. The zebrafish developmental anomalies arising from injection of mutant TWIST2 RNA and ChIP studies suggest two possible mechanisms: a dominant-negative effect due to loss of binding to the normal contingent of TWIST2 DNA binding sites or a neomorphic mechanism due to binding of the mutant TWIST2 to extraneous promoter sites. Supporting a contribution by the first mechanism is the phenotypic overlap with Setleis syndrome (MIM: 227260), a less severe ectodermal dysplasia characterized by bitemporal lesions as well as eyelash and eyebrow defects, [64] [65] [66] [67] [68] that has been associated with homozygous loss-of-function mutations in TWIST2. d. Seven target genes were chosen from RNA-Seq results for qPCR validation using transgenic lines. Compared to the wild type, p.Glu75Lys (E75K) appeared to be more potent than p.Glu75Gln (E75Q) in suppressing targeted genes. It is worth noting that fgl2 was enhanced in p.Glu75Gln (E75Q) but repressed by p.Glu75Lys (E75K), suggesting some difference between the two mutations in inducing the disease.
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Supplemental Figure Legends
Supplemental Table   TABLE S1 (p.Glu75Lys and p.Glus75Gln) under the control of a Cre-loxP inducible system were generated using a Tol2 based transgenic technology. Wild type or mutant TWIST2 cDNA were placed downstream of zebrafish β-actin promoter, in which mCherry-STOP signal with two loxP elements at the both ends was placed between TWIST2 gene sequence and β-actin promoter. Upon introduction of Cre, the mCherry-STOP cassette will be removed, functioning as an inducible element. Phenotypes of transgenic embryos were analyzed upon induction of Cre by heat at 38.5˚C for 30 minutes at 24hpf using heat-shock hs-Cre (+/-) and Twist2 (+/-) double transgenic zebrafish embryos. For qPCR, 60 transgenic embryos were heated at 38.5˚C for 30 minutes at 80% epiboly stage and then collected for RNA preparation in Trizol three hours later.
